Open-Label, Dose Escalation Phase I Study in Healthy Volunteers to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (MBL-HCV1) Against Hepatitis C E2 Glycoprotein.
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2017
At a glance
- Drugs MBL HCV1 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 25 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Dec 2009 Actual patient number (31) added as reported by ClinicalTrials.gov.
- 31 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.